Agger
Else Marie Agger, Copenhagen DK
Patent application number | Description | Published |
---|---|---|
20100310585 | THE USE OF MONOMYCOLYL GLYCEROL (MMG) AS AN ADJUVANT - Here we identify MMG and its alpha- and ketomycolic acid derivatives as highly bioactive lipids derived from | 12-09-2010 |
Else Marie Agger, Copenhagen S DK
Patent application number | Description | Published |
---|---|---|
20110250224 | ADJUVANT COMBINATIONS OF LIPOSOMES AND MYCOBACTERIAL LIPIDS FOR IMMUNIZATION COMPOSITIONS AND VACCINES - The present invention provides a vaccine adjuvant consisting of a combination of a surfactant i.e. dimethyldeoctadecylammonium-bromide/chloride (DDA) and a lipid extract from | 10-13-2011 |
20110287087 | MODIFIED CATIONIC LIPOSOME ADJUVANS - The present invention relates to the use of vaccines with adjuvants comprising cationic liposomes where neutral lipids has been incorporated into the liposomes to change the gel-liquid phase transition and thereby modifying the IgG sub-type response and enhancing the CD8 response of the liposomal adjuvant. This technology can be used to increase the production of IgG2 antibodies. This sub-type of anti-bodies (IgG2 in mice corresponding to IgG3 in humans) have been shown to selectively engage Fc activatory receptors on the surface of innate immune cells leading to enhanced proinflammatory responses and thereby a more efficient immune response with higher levels of protection in animal models of e.g. malaria and | 11-24-2011 |
20140205656 | MODIFIED CATIONIC LIPOSOME ADJUVANTS - The present invention relates to the use of vaccines with adjuvants comprising cationic liposomes where neutral lipids has been incorporated into the liposomes to change the gel-liquid phase transition and thereby modifying the IgG sub-type response and enhancing the CD8 response of the liposomal adjuvant. This technology can be used to increase the production of IgG2 antibodies. This sub-type of antibodies (IgG2 in mice corresponding to IgG3 in humans) have been shown to selectively engage Fc activatory receptors on the surface of innate immune cells leading to enhanced proinflammatory responses and thereby a more efficient immune response with higher levels of protection in animal models of e.g. malaria and | 07-24-2014 |
Karl Agger, Copenhagen DK
Patent application number | Description | Published |
---|---|---|
20090162945 | INHIBITION OF GASC1 - The present invention provides a method of testing the ability of a test compound to bind to and optionally modulate the activity of a protein of the JMJD2 subfamily of Jumonji proteins. The method comprises incubating a test compound with a protein of the JMJD2 subfamily of Jumonji proteins, a co-factor of said protein and, optionally, a substrate for demethylation. The method of the invention can be used for screening large numbers of compounds to identify a group of compounds that are candidate compounds for clinical use for treatment of certain cancers especially prostate cancers. Other compounds that do not have activity in the screening assays can be eliminated from further consideration as candidate compounds. The method of the invention therefore has utility in the pharmaceutical industry. | 06-25-2009 |
Marc S. Agger, Boston, MA US
Patent application number | Description | Published |
---|---|---|
20150104770 | SYSTEMS AND METHODS FOR PERSONALIZED INCENTIVE-BASED HEALTH SUPPORT - Systems and methods for creating a personalized health program are disclosed. The systems and methods may use a personalization engine to accept health data and condition specific actions and to output a list of at least one personalized action. The personalized actions may help patients in creating and sustaining behaviors to help improve health and productivity and lower healthcare costs. Such personalized health programs may use incentives to make such programs more effective. | 04-16-2015 |